Merck & Co. and Moderna maintain a decade-long collaboration centered on their personalized mRNA cancer vaccine intismeran autogene combined with Keytruda, which delivered statistically significant Phase 3 success in resected melanoma in August 2026, driving sharp share-price gains for both. This alliance already delivers substantial commercial and R&D synergies without requiring a full merger or acquisition, consistent with the 98.8% market-implied probability against such a deal being announced in 2026. Traders price in continued independent operations amid Keytruda’s patent cliff and Moderna’s post-COVID revenue shift. Tail risks remain low but include unforeseen regulatory setbacks or strategic pivots if either firm encounters acute capital needs or competitive threats that alter board-level incentives.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật1% khả năng
MỚI
MỚI
Dec 31, 2026
1% khả năng
MỚI
MỚI
Dec 31, 2026
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck & Co. and Moderna maintain a decade-long collaboration centered on their personalized mRNA cancer vaccine intismeran autogene combined with Keytruda, which delivered statistically significant Phase 3 success in resected melanoma in August 2026, driving sharp share-price gains for both. This alliance already delivers substantial commercial and R&D synergies without requiring a full merger or acquisition, consistent with the 98.8% market-implied probability against such a deal being announced in 2026. Traders price in continued independent operations amid Keytruda’s patent cliff and Moderna’s post-COVID revenue shift. Tail risks remain low but include unforeseen regulatory setbacks or strategic pivots if either firm encounters acute capital needs or competitive threats that alter board-level incentives.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Thị trường mở: Aug 19, 2026, 3:58 PM ET
Khối lượng
$430Ngày kết thúc
Jan 1, 2027Thị trường mở
Aug 19, 2026, 3:58 PM ETNgười giải quyết
0x65070BE91...This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Merck & Co. and Moderna maintain a decade-long collaboration centered on their personalized mRNA cancer vaccine intismeran autogene combined with Keytruda, which delivered statistically significant Phase 3 success in resected melanoma in August 2026, driving sharp share-price gains for both. This alliance already delivers substantial commercial and R&D synergies without requiring a full merger or acquisition, consistent with the 98.8% market-implied probability against such a deal being announced in 2026. Traders price in continued independent operations amid Keytruda’s patent cliff and Moderna’s post-COVID revenue shift. Tail risks remain low but include unforeseen regulatory setbacks or strategic pivots if either firm encounters acute capital needs or competitive threats that alter board-level incentives.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
Khối lượng
$430Ngày kết thúc
Jan 1, 2027Thị trường mở
Aug 19, 2026, 3:58 PM ETNgười giải quyết
0x65070BE91...Merck & Co. and Moderna maintain a decade-long collaboration centered on their personalized mRNA cancer vaccine intismeran autogene combined with Keytruda, which delivered statistically significant Phase 3 success in resected melanoma in August 2026, driving sharp share-price gains for both. This alliance already delivers substantial commercial and R&D synergies without requiring a full merger or acquisition, consistent with the 98.8% market-implied probability against such a deal being announced in 2026. Traders price in continued independent operations amid Keytruda’s patent cliff and Moderna’s post-COVID revenue shift. Tail risks remain low but include unforeseen regulatory setbacks or strategic pivots if either firm encounters acute capital needs or competitive threats that alter board-level incentives.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật
Cẩn thận với liên kết bên ngoài.
Cẩn thận với liên kết bên ngoài.
Câu hỏi thường gặp